401k Plan data: NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN plan

NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN 401k Plan overview

Plan Name	NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN
Plan identification number	001

NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN Benefits

401k Plan Type

Defined Contribution Pension

Plan Features/Benefits

Profit-sharing
ERISA section 404(c) Plan - This plan, or any part of it is intended to meet the conditions of 29 CFR 2550.404c-1.
Total participant-directed account plan - Participants have the opportunity to direct the investment of all the assets allocated to their individual accounts, regardless of whether 29 CFR 2550.404c-1 is intended to be met.
Code section 401(k) feature - A cash or deferred arrangement described in Code section 401(k) that is part of a qualified defined contribution plan that provides for an election by employees to defer part of their compensation or receive these amounts in cash.
Code section 401(m) arrangement - Employee contributions are allocated to separate accounts under the plan or employer contributions are based, in whole or in part, on employee deferrals or contribtions to the plan. Not applicable if plan is 401(k) plan with only QNECs and/or QMACs. Also not applicable if Code section 403(b)(1), 403(b)(7) or 408 arrangements/accounts/annuities.
Plan provides for automatic enrollment in plan that has employee contributions deducted from payroll.
Total or partial participant-directed account plan - plan uses default investment account for participants who fail to direct assets in their account.
Master plan - A pension plan that is made available by a sponsor for adoption by employers; that is the subject of a favorable opinion letter; and for which a single funding medium (for example, a trust or custodial account) is established for the joint use of all adopting employers.

401k Sponsoring company profile

NEUROSCIENCE, INC. has sponsored the creation of one or more 401k plans.

Company Name: NEUROSCIENCE, INC.

Employer identification number (EIN): 392004941

NAIC Classification: 541990
NAIC Description: All Other Professional, Scientific, and Technical Services

Form 5500 Filing Information

Submission information for form 5500 for 401k plan NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN

Plan id# Filing Submission Date Name of Administrator Date Administrator Signed Name of Company Sponsor Date Sponsor Signed
001 2018-01-01 BRENT BUBLITZ
001 2017-01-01 BRENT BUBLITZ
001 2016-01-01 BRENT BUBLITZ
001 2015-01-01 BRENT BUBLITZ
001 2014-01-01 BRENT BUBLITZ
001 2013-01-01 BRENT BUBLITZ
001 2012-01-01 BRENT BUBLITZ
001 2011-01-01 BRENT BUBLITZ

Plan id#	Filing Submission Date	Name of Administrator
001	2018-01-01	BRENT BUBLITZ
001	2017-01-01	BRENT BUBLITZ
001	2016-01-01	BRENT BUBLITZ
001	2015-01-01	BRENT BUBLITZ
001	2014-01-01	BRENT BUBLITZ
001	2013-01-01	BRENT BUBLITZ
001	2012-01-01	BRENT BUBLITZ
001	2011-01-01	BRENT BUBLITZ

Plan Statistics for NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN

401k plan membership statisitcs for NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN

Measure Date Value
2018: NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN 2018 401k membership
Total participants, beginning-of-year 2018-01-01 137
Total number of active participants reported on line 7a of the Form 5500 2018-01-01 0
Number of retired or separated participants receiving benefits 2018-01-01 0
Number of other retired or separated participants entitled to future benefits 2018-01-01 0
Total of all active and inactive participants 2018-01-01 0
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits 2018-01-01 0
Total participants 2018-01-01 0
Number of participants with account balances 2018-01-01 0
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested 2018-01-01 0
2017: NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN 2017 401k membership
Total participants, beginning-of-year 2017-01-01 163
Total number of active participants reported on line 7a of the Form 5500 2017-01-01 104
Number of other retired or separated participants entitled to future benefits 2017-01-01 33
Total of all active and inactive participants 2017-01-01 137
Total participants 2017-01-01 137
Number of participants with account balances 2017-01-01 140
2016: NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN 2016 401k membership
Total participants, beginning-of-year 2016-01-01 156
Total number of active participants reported on line 7a of the Form 5500 2016-01-01 119
Number of retired or separated participants receiving benefits 2016-01-01 0
Number of other retired or separated participants entitled to future benefits 2016-01-01 44
Total of all active and inactive participants 2016-01-01 163
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits 2016-01-01 0
Total participants 2016-01-01 163
Number of participants with account balances 2016-01-01 160
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested 2016-01-01 0
2015: NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN 2015 401k membership
Total participants, beginning-of-year 2015-01-01 166
Total number of active participants reported on line 7a of the Form 5500 2015-01-01 115
Number of other retired or separated participants entitled to future benefits 2015-01-01 41
Total of all active and inactive participants 2015-01-01 156
Total participants 2015-01-01 156
Number of participants with account balances 2015-01-01 156
2014: NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN 2014 401k membership
Total participants, beginning-of-year 2014-01-01 189
Total number of active participants reported on line 7a of the Form 5500 2014-01-01 119
Number of other retired or separated participants entitled to future benefits 2014-01-01 47
Total of all active and inactive participants 2014-01-01 166
Total participants 2014-01-01 166
Number of participants with account balances 2014-01-01 165
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested 2014-01-01 0
2013: NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN 2013 401k membership
Total participants, beginning-of-year 2013-01-01 179
Total number of active participants reported on line 7a of the Form 5500 2013-01-01 137
Number of other retired or separated participants entitled to future benefits 2013-01-01 52
Total of all active and inactive participants 2013-01-01 189
Total participants 2013-01-01 189
Number of participants with account balances 2013-01-01 187
2012: NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN 2012 401k membership
Total participants, beginning-of-year 2012-01-01 181
Total number of active participants reported on line 7a of the Form 5500 2012-01-01 124
Number of retired or separated participants receiving benefits 2012-01-01 0
Number of other retired or separated participants entitled to future benefits 2012-01-01 55
Total of all active and inactive participants 2012-01-01 179
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits 2012-01-01 0
Total participants 2012-01-01 179
Number of participants with account balances 2012-01-01 174
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested 2012-01-01 0
2011: NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN 2011 401k membership
Total participants, beginning-of-year 2011-01-01 168
Total number of active participants reported on line 7a of the Form 5500 2011-01-01 147
Number of retired or separated participants receiving benefits 2011-01-01 2
Number of other retired or separated participants entitled to future benefits 2011-01-01 32
Total of all active and inactive participants 2011-01-01 181
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits 2011-01-01 0
Total participants 2011-01-01 181
Number of participants with account balances 2011-01-01 160
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested 2011-01-01 0

Measure	Date	Value
2018: NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN 2018 401k membership
Total participants, beginning-of-year	2018-01-01	137
Total number of active participants reported on line 7a of the Form 5500	2018-01-01	0
Number of retired or separated participants receiving benefits	2018-01-01	0
Number of other retired or separated participants entitled to future benefits	2018-01-01	0
Total of all active and inactive participants	2018-01-01	0
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits	2018-01-01	0
Total participants	2018-01-01	0
Number of participants with account balances	2018-01-01	0
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested	2018-01-01	0
2017: NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN 2017 401k membership
Total participants, beginning-of-year	2017-01-01	163
Total number of active participants reported on line 7a of the Form 5500	2017-01-01	104
Number of other retired or separated participants entitled to future benefits	2017-01-01	33
Total of all active and inactive participants	2017-01-01	137
Total participants	2017-01-01	137
Number of participants with account balances	2017-01-01	140
2016: NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN 2016 401k membership
Total participants, beginning-of-year	2016-01-01	156
Total number of active participants reported on line 7a of the Form 5500	2016-01-01	119
Number of retired or separated participants receiving benefits	2016-01-01	0
Number of other retired or separated participants entitled to future benefits	2016-01-01	44
Total of all active and inactive participants	2016-01-01	163
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits	2016-01-01	0
Total participants	2016-01-01	163
Number of participants with account balances	2016-01-01	160
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested	2016-01-01	0
2015: NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN 2015 401k membership
Total participants, beginning-of-year	2015-01-01	166
Total number of active participants reported on line 7a of the Form 5500	2015-01-01	115
Number of other retired or separated participants entitled to future benefits	2015-01-01	41
Total of all active and inactive participants	2015-01-01	156
Total participants	2015-01-01	156
Number of participants with account balances	2015-01-01	156
2014: NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN 2014 401k membership
Total participants, beginning-of-year	2014-01-01	189
Total number of active participants reported on line 7a of the Form 5500	2014-01-01	119
Number of other retired or separated participants entitled to future benefits	2014-01-01	47
Total of all active and inactive participants	2014-01-01	166
Total participants	2014-01-01	166
Number of participants with account balances	2014-01-01	165
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested	2014-01-01	0
2013: NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN 2013 401k membership
Total participants, beginning-of-year	2013-01-01	179
Total number of active participants reported on line 7a of the Form 5500	2013-01-01	137
Number of other retired or separated participants entitled to future benefits	2013-01-01	52
Total of all active and inactive participants	2013-01-01	189
Total participants	2013-01-01	189
Number of participants with account balances	2013-01-01	187
2012: NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN 2012 401k membership
Total participants, beginning-of-year	2012-01-01	181
Total number of active participants reported on line 7a of the Form 5500	2012-01-01	124
Number of retired or separated participants receiving benefits	2012-01-01	0
Number of other retired or separated participants entitled to future benefits	2012-01-01	55
Total of all active and inactive participants	2012-01-01	179
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits	2012-01-01	0
Total participants	2012-01-01	179
Number of participants with account balances	2012-01-01	174
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested	2012-01-01	0
2011: NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN 2011 401k membership
Total participants, beginning-of-year	2011-01-01	168
Total number of active participants reported on line 7a of the Form 5500	2011-01-01	147
Number of retired or separated participants receiving benefits	2011-01-01	2
Number of other retired or separated participants entitled to future benefits	2011-01-01	32
Total of all active and inactive participants	2011-01-01	181
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits	2011-01-01	0
Total participants	2011-01-01	181
Number of participants with account balances	2011-01-01	160
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested	2011-01-01	0

Financial Data on NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN

Measure	Date	Value
2018 : NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN 2018 401k financial data
Total transfer of assets from this plan	2018-12-31	$1,931,168
Total income from all sources (including contributions)	2018-12-31	$129,513
Total of all expenses incurred	2018-12-31	$3,267,504
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others	2018-12-31	$3,267,487
Total contributions o plan (from employers,participants, others, non cash contrinutions)	2018-12-31	$170,069
Value of total assets at end of year	2018-12-31	$0
Value of total assets at beginning of year	2018-12-31	$5,069,159
Total of administrative expenses incurred including professional, contract, advisory and management fees	2018-12-31	$17
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year	2018-12-31	Yes
Value of any plan assets that reverted to the employer resulting from resoluton to terminate the plan	2018-12-31	$0
Was this plan covered by a fidelity bond	2018-12-31	Yes
Value of fidelity bond cover	2018-12-31	$500,000
If this is an individual account plan, was there a blackout period	2018-12-31	No
Were there any nonexempt tranactions with any party-in-interest	2018-12-31	No
Contributions received from participants	2018-12-31	$106,779
Income. Received or receivable in cash from other sources (including rollovers)	2018-12-31	$2,736
Administrative expenses (other) incurred	2018-12-31	$17
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser	2018-12-31	No
Value of net income/loss	2018-12-31	$-3,137,991
Value of net assets at end of year (total assets less liabilities)	2018-12-31	$0
Value of net assets at beginning of year (total assets less liabilities)	2018-12-31	$5,069,159
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond)	2018-12-31	No
Were any loans by the plan or fixed income obligations due to the plan in default	2018-12-31	No
Were any leases to which the plan was party in default or uncollectible	2018-12-31	No
Value of interest in common/collective trusts at end of year	2018-12-31	$0
Value of interest in common/collective trusts at beginning of year	2018-12-31	$5,069,159
Net investment gain or loss from common/collective trusts	2018-12-31	$-40,556
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets	2018-12-31	No
Was there a failure to transmit to the plan any participant contributions	2018-12-31	No
Has the plan failed to provide any benefit when due under the plan	2018-12-31	No
Contributions received in cash from employer	2018-12-31	$60,554
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers	2018-12-31	$3,267,487
Did the plan have assets held for investment	2018-12-31	No
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser	2018-12-31	No
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC	2018-12-31	Yes
Accountant perfomed limited scope audit pursuant to 29 CFR 2520.103-8 and/or 103-12(d)	2018-12-31	Yes
Opinion of an independent qualified public accountant for this plan	2018-12-31	Disclaimer
Accountancy firm name	2018-12-31	LURIE, LLP
Accountancy firm EIN	2018-12-31	410721734
2017 : NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN 2017 401k financial data
Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2017-12-31	$2,837
Total income from all sources (including contributions)	2017-12-31	$1,467,312
Total of all expenses incurred	2017-12-31	$806,121
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others	2017-12-31	$804,421
Total contributions o plan (from employers,participants, others, non cash contrinutions)	2017-12-31	$735,879
Value of total assets at end of year	2017-12-31	$5,069,159
Value of total assets at beginning of year	2017-12-31	$4,410,805
Total of administrative expenses incurred including professional, contract, advisory and management fees	2017-12-31	$1,700
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year	2017-12-31	No
Was this plan covered by a fidelity bond	2017-12-31	Yes
Value of fidelity bond cover	2017-12-31	$500,000
If this is an individual account plan, was there a blackout period	2017-12-31	No
Were there any nonexempt tranactions with any party-in-interest	2017-12-31	No
Contributions received from participants	2017-12-31	$467,355
Participant contributions at beginning of year	2017-12-31	$42,180
Other liabilities (not benefit claims, operating payabales oe acquisition indebtedness) at beginning of year	2017-12-31	$2,837
Administrative expenses (other) incurred	2017-12-31	$1,700
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser	2017-12-31	No
Value of net income/loss	2017-12-31	$661,191
Value of net assets at end of year (total assets less liabilities)	2017-12-31	$5,069,159
Value of net assets at beginning of year (total assets less liabilities)	2017-12-31	$4,407,968
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond)	2017-12-31	No
Were any loans by the plan or fixed income obligations due to the plan in default	2017-12-31	No
Were any leases to which the plan was party in default or uncollectible	2017-12-31	No
Value of interest in common/collective trusts at end of year	2017-12-31	$5,069,159
Value of interest in common/collective trusts at beginning of year	2017-12-31	$4,343,668
Net investment gain or loss from common/collective trusts	2017-12-31	$731,433
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets	2017-12-31	No
Was there a failure to transmit to the plan any participant contributions	2017-12-31	No
Has the plan failed to provide any benefit when due under the plan	2017-12-31	No
Contributions received in cash from employer	2017-12-31	$268,524
Employer contributions (assets) at beginning of year	2017-12-31	$24,957
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers	2017-12-31	$804,421
Did the plan have assets held for investment	2017-12-31	Yes
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser	2017-12-31	No
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC	2017-12-31	No
Accountant perfomed limited scope audit pursuant to 29 CFR 2520.103-8 and/or 103-12(d)	2017-12-31	Yes
Opinion of an independent qualified public accountant for this plan	2017-12-31	Disclaimer
Accountancy firm name	2017-12-31	LURIE, LLP
Accountancy firm EIN	2017-12-31	410721734
2016 : NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN 2016 401k financial data
Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2016-12-31	$2,837
Total income from all sources (including contributions)	2016-12-31	$1,034,693
Total of all expenses incurred	2016-12-31	$878,164
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others	2016-12-31	$875,327
Value of total corrective distributions	2016-12-31	$2,837
Total contributions o plan (from employers,participants, others, non cash contrinutions)	2016-12-31	$734,435
Value of total assets at end of year	2016-12-31	$4,410,805
Value of total assets at beginning of year	2016-12-31	$4,251,439
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year	2016-12-31	No
Was this plan covered by a fidelity bond	2016-12-31	Yes
Value of fidelity bond cover	2016-12-31	$440,796
If this is an individual account plan, was there a blackout period	2016-12-31	No
Were there any nonexempt tranactions with any party-in-interest	2016-12-31	No
Contributions received from participants	2016-12-31	$453,167
Participant contributions at end of year	2016-12-31	$42,180
Income. Received or receivable in cash from other sources (including rollovers)	2016-12-31	$10,988
Other liabilities (not benefit claims, operating payabales oe acquisition indebtedness) at end of year	2016-12-31	$2,837
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser	2016-12-31	No
Value of net income/loss	2016-12-31	$156,529
Value of net assets at end of year (total assets less liabilities)	2016-12-31	$4,407,968
Value of net assets at beginning of year (total assets less liabilities)	2016-12-31	$4,251,439
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond)	2016-12-31	No
Were any loans by the plan or fixed income obligations due to the plan in default	2016-12-31	No
Were any leases to which the plan was party in default or uncollectible	2016-12-31	No
Value of interest in common/collective trusts at end of year	2016-12-31	$4,343,668
Value of interest in common/collective trusts at beginning of year	2016-12-31	$4,251,439
Net investment gain or loss from common/collective trusts	2016-12-31	$300,258
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets	2016-12-31	No
Was there a failure to transmit to the plan any participant contributions	2016-12-31	No
Has the plan failed to provide any benefit when due under the plan	2016-12-31	No
Contributions received in cash from employer	2016-12-31	$270,280
Employer contributions (assets) at end of year	2016-12-31	$24,957
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers	2016-12-31	$875,327
Did the plan have assets held for investment	2016-12-31	Yes
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser	2016-12-31	No
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC	2016-12-31	No
Accountant perfomed limited scope audit pursuant to 29 CFR 2520.103-8 and/or 103-12(d)	2016-12-31	Yes
Opinion of an independent qualified public accountant for this plan	2016-12-31	Disclaimer
Accountancy firm name	2016-12-31	LURIE, LLP
Accountancy firm EIN	2016-12-31	410721734
2015 : NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN 2015 401k financial data
Total income from all sources (including contributions)	2015-12-31	$609,358
Total of all expenses incurred	2015-12-31	$815,762
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others	2015-12-31	$815,762
Total contributions o plan (from employers,participants, others, non cash contrinutions)	2015-12-31	$674,937
Value of total assets at end of year	2015-12-31	$4,251,439
Value of total assets at beginning of year	2015-12-31	$4,457,843
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year	2015-12-31	No
Was this plan covered by a fidelity bond	2015-12-31	Yes
Value of fidelity bond cover	2015-12-31	$425,143
If this is an individual account plan, was there a blackout period	2015-12-31	No
Were there any nonexempt tranactions with any party-in-interest	2015-12-31	No
Contributions received from participants	2015-12-31	$427,326
Value of other receiveables (less allowance for doubtful accounts) at beginning of year	2015-12-31	$2,070
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser	2015-12-31	No
Value of net income/loss	2015-12-31	$-206,404
Value of net assets at end of year (total assets less liabilities)	2015-12-31	$4,251,439
Value of net assets at beginning of year (total assets less liabilities)	2015-12-31	$4,457,843
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond)	2015-12-31	No
Were any loans by the plan or fixed income obligations due to the plan in default	2015-12-31	No
Were any leases to which the plan was party in default or uncollectible	2015-12-31	No
Value of interest in common/collective trusts at end of year	2015-12-31	$4,251,439
Value of interest in common/collective trusts at beginning of year	2015-12-31	$4,455,773
Net investment gain or loss from common/collective trusts	2015-12-31	$-65,579
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets	2015-12-31	No
Was there a failure to transmit to the plan any participant contributions	2015-12-31	No
Has the plan failed to provide any benefit when due under the plan	2015-12-31	No
Contributions received in cash from employer	2015-12-31	$247,611
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers	2015-12-31	$815,762
Did the plan have assets held for investment	2015-12-31	Yes
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser	2015-12-31	No
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC	2015-12-31	No
Accountant perfomed limited scope audit pursuant to 29 CFR 2520.103-8 and/or 103-12(d)	2015-12-31	Yes
Opinion of an independent qualified public accountant for this plan	2015-12-31	Disclaimer
Accountancy firm name	2015-12-31	LURIE, LLP
Accountancy firm EIN	2015-12-31	410721734
2014 : NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN 2014 401k financial data
Total income from all sources (including contributions)	2014-12-31	$1,085,370
Total of all expenses incurred	2014-12-31	$597,613
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others	2014-12-31	$594,814
Total contributions o plan (from employers,participants, others, non cash contrinutions)	2014-12-31	$865,139
Value of total assets at end of year	2014-12-31	$4,457,843
Value of total assets at beginning of year	2014-12-31	$3,970,086
Total of administrative expenses incurred including professional, contract, advisory and management fees	2014-12-31	$2,799
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year	2014-12-31	No
Administrative expenses professional fees incurred	2014-12-31	$2,799
Was this plan covered by a fidelity bond	2014-12-31	Yes
Value of fidelity bond cover	2014-12-31	$445,577
If this is an individual account plan, was there a blackout period	2014-12-31	No
Were there any nonexempt tranactions with any party-in-interest	2014-12-31	No
Contributions received from participants	2014-12-31	$481,311
Income. Received or receivable in cash from other sources (including rollovers)	2014-12-31	$83,339
Value of other receiveables (less allowance for doubtful accounts) at end of year	2014-12-31	$2,070
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser	2014-12-31	No
Value of net income/loss	2014-12-31	$487,757
Value of net assets at end of year (total assets less liabilities)	2014-12-31	$4,457,843
Value of net assets at beginning of year (total assets less liabilities)	2014-12-31	$3,970,086
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond)	2014-12-31	No
Were any loans by the plan or fixed income obligations due to the plan in default	2014-12-31	No
Were any leases to which the plan was party in default or uncollectible	2014-12-31	No
Value of interest in common/collective trusts at end of year	2014-12-31	$4,455,773
Value of interest in common/collective trusts at beginning of year	2014-12-31	$3,970,086
Net investment gain or loss from common/collective trusts	2014-12-31	$220,231
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets	2014-12-31	No
Was there a failure to transmit to the plan any participant contributions	2014-12-31	No
Has the plan failed to provide any benefit when due under the plan	2014-12-31	No
Contributions received in cash from employer	2014-12-31	$300,489
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers	2014-12-31	$594,814
Did the plan have assets held for investment	2014-12-31	Yes
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser	2014-12-31	No
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC	2014-12-31	No
Accountant perfomed limited scope audit pursuant to 29 CFR 2520.103-8 and/or 103-12(d)	2014-12-31	Yes
Opinion of an independent qualified public accountant for this plan	2014-12-31	Disclaimer
Accountancy firm name	2014-12-31	LURIE BESIKOF LAPIDUS & COMPANY LLP
Accountancy firm EIN	2014-12-31	410721734
2013 : NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN 2013 401k financial data
Total income from all sources (including contributions)	2013-12-31	$1,352,898
Total of all expenses incurred	2013-12-31	$438,907
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others	2013-12-31	$438,907
Total contributions o plan (from employers,participants, others, non cash contrinutions)	2013-12-31	$671,764
Value of total assets at end of year	2013-12-31	$3,970,086
Value of total assets at beginning of year	2013-12-31	$3,056,095
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year	2013-12-31	No
Was this plan covered by a fidelity bond	2013-12-31	Yes
Value of fidelity bond cover	2013-12-31	$397,008
If this is an individual account plan, was there a blackout period	2013-12-31	No
Were there any nonexempt tranactions with any party-in-interest	2013-12-31	No
Contributions received from participants	2013-12-31	$411,492
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser	2013-12-31	No
Value of net income/loss	2013-12-31	$913,991
Value of net assets at end of year (total assets less liabilities)	2013-12-31	$3,970,086
Value of net assets at beginning of year (total assets less liabilities)	2013-12-31	$3,056,095
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond)	2013-12-31	No
Were any loans by the plan or fixed income obligations due to the plan in default	2013-12-31	No
Were any leases to which the plan was party in default or uncollectible	2013-12-31	No
Value of interest in common/collective trusts at end of year	2013-12-31	$3,970,086
Value of interest in common/collective trusts at beginning of year	2013-12-31	$3,056,095
Net investment gain or loss from common/collective trusts	2013-12-31	$681,134
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets	2013-12-31	No
Was there a failure to transmit to the plan any participant contributions	2013-12-31	No
Has the plan failed to provide any benefit when due under the plan	2013-12-31	No
Contributions received in cash from employer	2013-12-31	$260,272
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers	2013-12-31	$438,907
Did the plan have assets held for investment	2013-12-31	Yes
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser	2013-12-31	No
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC	2013-12-31	No
Accountant perfomed limited scope audit pursuant to 29 CFR 2520.103-8 and/or 103-12(d)	2013-12-31	Yes
Opinion of an independent qualified public accountant for this plan	2013-12-31	Disclaimer
Accountancy firm name	2013-12-31	LURIE BESIKOF LAPIDUS & COMPANY LLP
Accountancy firm EIN	2013-12-31	410721734
2012 : NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN 2012 401k financial data
Unrealized appreciation/depreciation of real estate assets	2012-12-31	$0
Unrealized appreciation/depreciation of other (non real estate) assets	2012-12-31	$25,483
Total unrealized appreciation/depreciation of assets	2012-12-31	$25,483
Expenses. Interest paid	2012-12-31	$0
Amount of participant contributions which was failed to transmit to the plan within the time period described in 29 CFR 251.3-102	2012-12-31	$0
Total income from all sources (including contributions)	2012-12-31	$937,001
Total loss/gain on sale of assets	2012-12-31	$0
Total of all expenses incurred	2012-12-31	$452,587
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others	2012-12-31	$452,587
Expenses. Certain deemed distributions of participant loans	2012-12-31	$0
Value of total corrective distributions	2012-12-31	$0
Total contributions o plan (from employers,participants, others, non cash contrinutions)	2012-12-31	$720,066
Value of total assets at end of year	2012-12-31	$3,056,095
Value of total assets at beginning of year	2012-12-31	$2,571,681
Total of administrative expenses incurred including professional, contract, advisory and management fees	2012-12-31	$0
Total income from rents	2012-12-31	$0
Total interest from all sources	2012-12-31	$0
Total dividends received (eg from common stock, registered investment company shares)	2012-12-31	$0
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year	2012-12-31	No
Total dividends received from registered investment company shares (eg mutual funds)	2012-12-31	$0
Administrative expenses professional fees incurred	2012-12-31	$0
Was this plan covered by a fidelity bond	2012-12-31	Yes
Value of fidelity bond cover	2012-12-31	$305,610
If this is an individual account plan, was there a blackout period	2012-12-31	No
Total value of distributions paid in property other than in cash, annuity contracts, or publicly traded employer securities	2012-12-31	$0
Were there any nonexempt tranactions with any party-in-interest	2012-12-31	No
Contributions received from participants	2012-12-31	$455,852
Income. Received or receivable in cash from other sources (including rollovers)	2012-12-31	$0
Expenses. Other payments made (not to insurance carriers or or participants/beneficiaries)	2012-12-31	$0
Other income not declared elsewhere	2012-12-31	$0
Administrative expenses (other) incurred	2012-12-31	$0
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser	2012-12-31	No
Income. Non cash contributions	2012-12-31	$0
Value of net income/loss	2012-12-31	$484,414
Value of net assets at end of year (total assets less liabilities)	2012-12-31	$3,056,095
Value of net assets at beginning of year (total assets less liabilities)	2012-12-31	$2,571,681
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond)	2012-12-31	No
Were any loans by the plan or fixed income obligations due to the plan in default	2012-12-31	No
Were any leases to which the plan was party in default or uncollectible	2012-12-31	No
Investment advisory and management fees	2012-12-31	$0
Value of interest in registered invesment companies (eg mutual funds) at beginning of year	2012-12-31	$2,153,009
Interest on participant loans	2012-12-31	$0
Income. Interest from loans (other than to participants)	2012-12-31	$0
Interest earned on other investments	2012-12-31	$0
Income. Interest from US Government securities	2012-12-31	$0
Income. Interest from corporate debt instruments	2012-12-31	$0
Value of interest in common/collective trusts at end of year	2012-12-31	$3,056,095
Value of interest in common/collective trusts at beginning of year	2012-12-31	$418,672
Interest earned from interest bearing cash (including money market accounts and certificates of deposit)	2012-12-31	$0
Expenses. Payments to insurance carriers foe the provision of benefits	2012-12-31	$0
Net investment gain/loss from registered investment companies (e.g. mutual funds)	2012-12-31	$0
Net investment gain/loss from pooled separate accounts	2012-12-31	$0
Net investment gain or loss from common/collective trusts	2012-12-31	$191,452
Net gain/loss from 103.12 investment entities	2012-12-31	$0
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets	2012-12-31	No
Was there a failure to transmit to the plan any participant contributions	2012-12-31	No
Has the plan failed to provide any benefit when due under the plan	2012-12-31	No
Contributions received in cash from employer	2012-12-31	$264,214
Income. Dividends from preferred stock	2012-12-31	$0
Income. Dividends from common stock	2012-12-31	$0
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers	2012-12-31	$452,587
Contract administrator fees	2012-12-31	$0
Was the provided the required notice or one of the exceptions to providing the black out period notice applied under 29 CFR 2520.101-3	2012-12-31	No
Did the plan have assets held for investment	2012-12-31	Yes
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser	2012-12-31	No
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC	2012-12-31	No
Aggregate proceeds on sale of assets	2012-12-31	$0
Aggregate carrying amount (costs) on sale of assets	2012-12-31	$0
Accountant perfomed limited scope audit pursuant to 29 CFR 2520.103-8 and/or 103-12(d)	2012-12-31	Yes
Opinion of an independent qualified public accountant for this plan	2012-12-31	Disclaimer
Accountancy firm name	2012-12-31	LURIE BESIKOF LAPIDUS & COMPANY, LL
Accountancy firm EIN	2012-12-31	410721734
2011 : NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN 2011 401k financial data
Total unrealized appreciation/depreciation of assets	2011-12-31	$0
Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2011-12-31	$0
Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2011-12-31	$0
Total income from all sources (including contributions)	2011-12-31	$793,831
Total loss/gain on sale of assets	2011-12-31	$0
Total of all expenses incurred	2011-12-31	$133,787
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others	2011-12-31	$102,088
Total contributions o plan (from employers,participants, others, non cash contrinutions)	2011-12-31	$814,799
Value of total assets at end of year	2011-12-31	$2,571,681
Value of total assets at beginning of year	2011-12-31	$1,911,637
Total of administrative expenses incurred including professional, contract, advisory and management fees	2011-12-31	$31,699
Total interest from all sources	2011-12-31	$0
Total dividends received (eg from common stock, registered investment company shares)	2011-12-31	$0
Was this plan covered by a fidelity bond	2011-12-31	Yes
Value of fidelity bond cover	2011-12-31	$125,000
If this is an individual account plan, was there a blackout period	2011-12-31	No
Total value of distributions paid in property other than in cash, annuity contracts, or publicly traded employer securities	2011-12-31	$0
Were there any nonexempt tranactions with any party-in-interest	2011-12-31	No
Contributions received from participants	2011-12-31	$476,708
Income. Received or receivable in cash from other sources (including rollovers)	2011-12-31	$64,232
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser	2011-12-31	No
Value of net income/loss	2011-12-31	$660,044
Value of net assets at end of year (total assets less liabilities)	2011-12-31	$2,571,681
Value of net assets at beginning of year (total assets less liabilities)	2011-12-31	$1,911,637
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond)	2011-12-31	No
Were any loans by the plan or fixed income obligations due to the plan in default	2011-12-31	No
Were any leases to which the plan was party in default or uncollectible	2011-12-31	No
Investment advisory and management fees	2011-12-31	$31,699
Value of interest in registered invesment companies (eg mutual funds) at end of year	2011-12-31	$2,153,009
Value of interest in registered invesment companies (eg mutual funds) at beginning of year	2011-12-31	$1,635,262
Value of interest in common/collective trusts at end of year	2011-12-31	$418,672
Value of interest in common/collective trusts at beginning of year	2011-12-31	$276,375
Net investment gain/loss from registered investment companies (e.g. mutual funds)	2011-12-31	$-21,819
Net investment gain or loss from common/collective trusts	2011-12-31	$851
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets	2011-12-31	No
Was there a failure to transmit to the plan any participant contributions	2011-12-31	No
Has the plan failed to provide any benefit when due under the plan	2011-12-31	No
Contributions received in cash from employer	2011-12-31	$273,859
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers	2011-12-31	$102,088
Did the plan have assets held for investment	2011-12-31	Yes
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser	2011-12-31	No
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC	2011-12-31	No
Accountant perfomed limited scope audit pursuant to 29 CFR 2520.103-8 and/or 103-12(d)	2011-12-31	Yes
Opinion of an independent qualified public accountant for this plan	2011-12-31	Disclaimer
Accountancy firm name	2011-12-31	LURIE BESIKOF LAPIDUS & COMPANY,LLP
Accountancy firm EIN	2011-12-31	410721734
2010 : NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN 2010 401k financial data
Total unrealized appreciation/depreciation of assets	2010-12-31	$0
Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2010-12-31	$0
Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2010-12-31	$0
Total income from all sources (including contributions)	2010-12-31	$924,817
Total loss/gain on sale of assets	2010-12-31	$7,090
Total of all expenses incurred	2010-12-31	$47,950
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others	2010-12-31	$32,992
Total contributions o plan (from employers,participants, others, non cash contrinutions)	2010-12-31	$707,982
Value of total assets at end of year	2010-12-31	$1,911,637
Value of total assets at beginning of year	2010-12-31	$1,034,770
Total of administrative expenses incurred including professional, contract, advisory and management fees	2010-12-31	$14,958
Total interest from all sources	2010-12-31	$0
Total dividends received (eg from common stock, registered investment company shares)	2010-12-31	$0
Was this plan covered by a fidelity bond	2010-12-31	Yes
Value of fidelity bond cover	2010-12-31	$500,000
If this is an individual account plan, was there a blackout period	2010-12-31	No
Total value of distributions paid in property other than in cash, annuity contracts, or publicly traded employer securities	2010-12-31	$0
Were there any nonexempt tranactions with any party-in-interest	2010-12-31	No
Contributions received from participants	2010-12-31	$422,262
Income. Received or receivable in cash from other sources (including rollovers)	2010-12-31	$39,154
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser	2010-12-31	No
Value of net income/loss	2010-12-31	$876,867
Value of net assets at end of year (total assets less liabilities)	2010-12-31	$1,911,637
Value of net assets at beginning of year (total assets less liabilities)	2010-12-31	$1,034,770
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond)	2010-12-31	No
Were any loans by the plan or fixed income obligations due to the plan in default	2010-12-31	No
Were any leases to which the plan was party in default or uncollectible	2010-12-31	No
Investment advisory and management fees	2010-12-31	$14,958
Value of interest in registered invesment companies (eg mutual funds) at end of year	2010-12-31	$1,635,262
Value of interest in registered invesment companies (eg mutual funds) at beginning of year	2010-12-31	$879,633
Value of interest in common/collective trusts at end of year	2010-12-31	$276,375
Value of interest in common/collective trusts at beginning of year	2010-12-31	$155,137
Net investment gain/loss from registered investment companies (e.g. mutual funds)	2010-12-31	$207,554
Net investment gain or loss from common/collective trusts	2010-12-31	$2,191
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets	2010-12-31	No
Was there a failure to transmit to the plan any participant contributions	2010-12-31	No
Has the plan failed to provide any benefit when due under the plan	2010-12-31	No
Contributions received in cash from employer	2010-12-31	$246,566
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers	2010-12-31	$32,992
Did the plan have assets held for investment	2010-12-31	No
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser	2010-12-31	No
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC	2010-12-31	No
Aggregate proceeds on sale of assets	2010-12-31	$125,977
Aggregate carrying amount (costs) on sale of assets	2010-12-31	$118,887
Accountant perfomed limited scope audit pursuant to 29 CFR 2520.103-8 and/or 103-12(d)	2010-12-31	Yes
Opinion of an independent qualified public accountant for this plan	2010-12-31	Disclaimer
Accountancy firm name	2010-12-31	LURIE BESIKOF LAPIDUS & COMPANY,LLP
Accountancy firm EIN	2010-12-31	410721734

Form 5500 Responses for NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN

2018: NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN 2018 form 5500 responses
2018-01-01	Type of plan entity	Single employer plan
2018-01-01	This submission is the final filing	Yes
2018-01-01	Plan funding arrangement – Trust	Yes
2018-01-01	Plan benefit arrangement - Trust	Yes
2017: NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN 2017 form 5500 responses
2017-01-01	Type of plan entity	Single employer plan
2017-01-01	Plan funding arrangement – Trust	Yes
2017-01-01	Plan benefit arrangement - Trust	Yes
2016: NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN 2016 form 5500 responses
2016-01-01	Type of plan entity	Single employer plan
2016-01-01	Plan funding arrangement – Trust	Yes
2016-01-01	Plan benefit arrangement - Trust	Yes
2015: NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN 2015 form 5500 responses
2015-01-01	Type of plan entity	Single employer plan
2015-01-01	Plan funding arrangement – Trust	Yes
2015-01-01	Plan benefit arrangement - Trust	Yes
2014: NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN 2014 form 5500 responses
2014-01-01	Type of plan entity	Single employer plan
2014-01-01	Plan funding arrangement – Trust	Yes
2014-01-01	Plan benefit arrangement - Trust	Yes
2013: NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN 2013 form 5500 responses
2013-01-01	Type of plan entity	Single employer plan
2013-01-01	Plan funding arrangement – Trust	Yes
2013-01-01	Plan benefit arrangement - Trust	Yes
2012: NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN 2012 form 5500 responses
2012-01-01	Type of plan entity	Single employer plan
2012-01-01	Plan funding arrangement – Trust	Yes
2012-01-01	Plan benefit arrangement - Trust	Yes
2011: NEUROSCIENCE / PHARMASAN LABS 401(K) PLAN 2011 form 5500 responses
2011-01-01	Type of plan entity	Single employer plan
2011-01-01	Submission has been amended	No
2011-01-01	This submission is the final filing	No
2011-01-01	This return/report is a short plan year return/report (less than 12 months)	No
2011-01-01	Plan is a collectively bargained plan	No
2011-01-01	Plan funding arrangement – Trust	Yes
2011-01-01	Plan benefit arrangement - Trust	Yes

Was this data useful?

If you found the data here useful, PLEASE HELP US. We are a start-up and believe in making information freely available. By linking to us, posting on twitter, facebook and linkedin about us and generally spreading the word, you'll help us to grow. Our vision is to provide high quality data about the activities of all the companies in the world and where possible make it free to use and view. Finding and integrating data from thousands of data sources is time consuming and needs lots of effort. By simply spreading the word about us, you will help us. Please use the share buttons. It will only take a few seconds of your time. Thanks for helping

Information Disclaimer

The information provided on this website is not advice, endorsement or recommendation
The information published is supplied by third parties so we make no warranty on the accuracy, completeness etc. This information is provided "as-is". The information is subject to change as we obtain updates and corrections from the primary information sources.
You are free to use the information for your own personal research on the understanding to do so is at your own risk.

See full terms and conditions

Company Name:	NEUROSCIENCE, INC.
Employer identification number (EIN):	392004941
NAIC Classification:	541990
NAIC Description:	All Other Professional, Scientific, and Technical Services